Children (Newborn to 12 years)

Active Resources: 6

Articles: 3

  • FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics

    The FDA has approved a single-pill combination of rilpivirine + emtricitabine + tenofovir alafenamide (TAF); its brand name is Odefsey.

    It is intended for initial treatment of HIV-1-infected persons age 12 years and older whose pretreatment HIV RNA is ≤100,000 copies/mL, or as a substitute...

  • Once-Daily Dosing of Lamivudine and Abacavir for Pediatric Patients

    The U.S. Food and Drug Administration has approved once-daily dosing recommendations for lamivudine and abacavir for HIV-infected children. Previously, these NRTIs were approved only for twice-daily dosing in children. The dosing revisions apply to both the oral solution and the tablet...

  • Fast Takes: Darunavir Once-Daily Dosing for Children

    The FDA recently approved revisions to the pediatric dosing recommendations for darunavir tablets and oral suspension. Once-daily dosing of darunavir + ritonavir is recommended for children 3 years of age and older, and >10 kg in weight, who are treatment naive or whose HIV virus does not...

Day Title
Back to HIV Basics
Event type: Webinars
2018 National Ryan White Conference on HIV Care and Treatment & 2018 Clinical Conference at the National Ryan White Conference on HIV Care & Treatment